Skip to main content

Table 1 Characteristics of the study population

From: Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial

 Placebo groupNutraceutical groupTotalp-value
N (%)Mean (SD)N (%)Mean (SD)N (%)Mean (SD)
Sex
 Male28 (53.8) 30 (56.6) 58 (55.2) 0.85
 Female24 (46.2) 23 (43.4) 47 (44.8) 
 Total52 (100) 53 (100) 105 (100) 
Age 51.5 (13.2) 51.7 (13.0) 51.6 (13.1)0.95
Previous obstructive uropathy19 (36.5) 21 (39.6) 40 (38.1) 0.84
Previous stenting19 (36.5) 22 (41.5) 41 (39) 0.69
Urolithiasis as cause of current implantation41 (78.8) 41 (77.4) 82 (78.1) 0.85
Type of calculi
 Calcium oxalate19 (46.3) 21 (51.2) 40 (48.8) 0.80
 Others22 (53.7) 20 (48.7) 42 (51.2) 
 Total41 (100) 41 (100) 82 (100) 
Stent material
 Polyurethane23 (44.3) 20 (37.7) 43 (40.9) 0.45
 Silicone1 (1.9) 0 (0) 1 (1) 
 Percuflex28 (53.8) 33 (62.3) 61 (58.1) 
Implantation period (days) 39.7 (14.9) 35.4 (12.7) 37.54 (13.9)0.12
Basal urinary pH43 (100)6.2 (0.6)44 (100)6.3 (0.8)87 (100)6.3 (0.7)0.62
  1. SD standard deviation
  2. Group homogeneity at baseline